Licensed vaccine
Pneumovax 23
FDA-licensed vaccine · Merck Sharp & Dohme Corp. · STN BLA 101094
Key facts
| Trade name | Pneumovax 23 |
|---|---|
| Proper name | Pneumococcal Vaccine, Polyvalent |
| Manufacturer | Merck Sharp & Dohme Corp. |
| Submission tracking number (STN) | BLA 101094 |
| Recent FDA documents | October 27, 2021 Approval Letter - PNEUMOVAX 23, September 25, 2020 Approval Letter - PNEUMOVAX 23, November 26, 2019 Approval Letter - PNEUMOVAX 23, Patient Information - PNEUMOVAX 23, Package Insert - PNEUMOVAX 23, Supporting Documents older than three years - PNEUMOVAX 23 |
| FDA page updated | Oct 28, 2021 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: